The ER+/ HER2 -ve Breast Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
ER+/ HER2 -ve Breast Cancer: An Overview
HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help stop tumour growth.
ER+/ HER2 -ve Breast Cancer Market Key Facts
-
As per DelveInsight, among the 7MM, the most incident cases of ER+/HER– breast cancer were recorded in the United States.
-
The lowest incident population of ER+/HER– breast cancer were recorded in Japan among the 7MM.
-
As per DelveInsight, the ER-positive/HER2-negative Breast Cancer Market Size is anticipated to increase during the study period owing to the increasing incident population of ER+/HER2-ve Breast Cancer patients and the expected entry of premium price asset.
ER+/ HER2 -ve Breast Cancer Market
ER-positive/HER2-negative Breast Cancer Market Size was found to be USD 5,237.2 Million in 2017 in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted ER+/ HER2 -ve Breast Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the ER+/ HER2 -ve Breast Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
ER+/ HER2 -ve Breast Cancer Epidemiology
The epidemiology section covers insights into the historical and current ER+/ HER2 -ve Breast Cancer patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
ER+/ HER2 -ve Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ER+/ HER2 -ve Breast Cancer market or expected to get launched in the market during the study period. The analysis covers ER+/ HER2 -ve Breast Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the ER+/ HER2 -ve Breast Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market
ER+/ HER2 -ve Breast Cancer Therapeutics Analysis
The available therapeutics treatment options in ER-positive/HER2-negative Breast Cancer Landscape aim to reduce the survival rate of the patient population. Conventionally, endocrine therapies are recommended as first-line treatment management options for ER-Positive breast cancer. And, if ET does not respond well then chemotherapy is suggested by the oncologist.
Some of the key companies in the ER+/ HER2 -ve Breast Cancer Market include:
-
Jiangsu HengRui Medicine
-
Odonate Therapeutics
-
Merck Sharp and Dohme
-
GlaxoSmithKline
-
Pfizer
-
Novartis
-
AstraZeneca Pharmaceuticals
-
Eli Lilly
-
Pharmacia and Upjohn Company
-
Radius Pharmaceuticals
-
Immunomedics
-
Roche
-
Syndax Pharmaceuticals
-
Merrimack Pharmaceuticals
-
Takeda Pharmaceuticals
-
Eagle Pharmaceuticals
-
Bayer
And many others.
ER+/ HER2 -ve Breast Cancer Therapies covered in the report include:
-
Pembrolizumab
-
Sapanisertib
-
GSK525762
-
Radium-223 dichloride
-
Entinostat
-
Venclexta
-
Ipatasertib
-
Sacituzumab govitecan
-
Elacestrant (RAD1901)
-
Tesetaxel
-
SHR6390
And many others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market
Table of Content (ToC)
1. Key Insights
2. Executive Summary
3. ER+/ HER2 -ve Breast Cancer Competitive Intelligence Analysis
4. ER+/ HER2 -ve Breast Cancer Market Overview at a Glance
5. ER+/ HER2 -ve Breast Cancer Disease Background and Overview
6. ER+/ HER2 -ve Breast Cancer Patient Journey
7. ER+/ HER2 -ve Breast Cancer Epidemiology and Patient Population
8. ER+/ HER2 -ve Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. ER+/ HER2 -ve Breast Cancer Unmet Needs
10. Key Endpoints of ER+/ HER2 -ve Breast Cancer Treatment
11. ER+/ HER2 -ve Breast Cancer Marketed Products
12. ER+/ HER2 -ve Breast Cancer Emerging Therapies
13. ER+/ HER2 -ve Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. ER+/ HER2 -ve Breast Cancer Market Outlook (7 major markets)
16. ER+/ HER2 -ve Breast Cancer Access and Reimbursement Overview
17. KOL Views on the ER+/ HER2 -ve Breast Cancer Market.
18. ER+/ HER2 -ve Breast Cancer Market Drivers
19. ER+/ HER2 -ve Breast Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market
Other Latest Reports By DelveInsight
DelveInsight’s “Emphysema Market” report delivers an in-depth understanding of the Emphysema, historical and forecasted epidemiology as well as the Emphysema market size, share, and trends in the 7MM.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/